Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I
Completed
Grünenthal GmbH
Phase 2/Phase 3
This clinical trial is being conducted to demonstrate the efficacy of neridronic acid in the
treatment of pain associated with complex regional pain syndrome type I (CRPS-I).
The trial is divided into 3 periods: a 60-day enrollment period, a 12-week trial period, and
an extended follow-up period with visits at Month 6, Month 9, and Month 12. The extended
follow-up period will be terminated for all participants after the last participant enrolled
completes their Month 6 visit (Visit 9). The double-blind will be maintained throughout the
12-week trial period and extended follow-up period.
The aim of this trial was to investigate the safety of intravenous neridronic acid in
patients with complex regional pain syndrome (CRPS).
The trial was divided into 3 periods: a 60-day enrollment period, a treatment period
consisting of 4 infusions over 10 days, and a follow-up period of approximately 50 weeks
(with visits at Week 2, Week 6, Week 12, Week 26, Week 39, and Week 52).
Efficacy and Safety of Intravenous Neridronic Acid in CRPS
Terminated
Grünenthal GmbH
Phase 3
The aim of this trial was to investigate the efficacy and safety of intravenous neridronic
acid in subjects with Complex Regional Pain Syndrome (CRPS).
The trial consisted of an Enrollment Period lasting up to 60 days, Treatment Period A
consisting of 4 infusions (neridronic acid or placebo) over 10 days, and a Follow-up Period 1
until Week 26.
At Week 26, participants not meeting the pre-specified criteria to continue into Treatment
Period B continued in Follow-up Period 2 until Week 52. Participants meeting the
pre-specified criteria entered the open-label Treatment Period B with 4 additional infusions
(neridronic acid) over 10 days and follow-up visits until Week 52.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.